Profile: Sanofi SA (SNY.N)
7 Mar 2014
Sanofi, formerly Sanofi-Aventis, incorporated in 1994, is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. As of February 2011, Sanofi portfolio comprised 55 projects in clinical development, of which 13 were in Phase III or had been submitted to the health authorities for approval. Sanofi has a portfolio of prescription drugs, vaccines, generics and consumer healthcare products. In December 2011, Sanofi announced that it completed the divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International, Inc. Effective March 5, 2014, Sanofi SA of France acquired an undisclosed minority stake in Regulus Therapeutics Inc.
On June 22, 2011, the Company announced that it had entered into a global agreement with Medco Health Solutions, Inc. (Medco) and United BioSource corporations (UBC), a wholly owned subsidiary of Medco to leverage the real-world evidence generated during product development and throughout the product lifecycle. Under the terms of this multi-year agreement, Medco and UBC will provide real-world input and comparative data into product development strategy.
On June 16, 2011, the Company had entered into a two-year research collaboration with the biopharmaceutical company Audion Therapeutics to develop treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach. As part of Sanofi’s new research and development model, five Therapeutic Strategic Units (TSUs) were created with a focus on major patho-physiologies, pressing public health needs or major geographic areas: Aging Fibrosis and Wound Repair, Immuno-Inflammation, Infectious Diseases and the Asia-Pacific Unit.
As of June 22, 2011, the Company’s advanced-stage research and development portfolio included Lixisenatide, Teriflunomide, Ombrabulin and BSI-201. On February 2011, Sanofi announced the Phase III results of GETGOAL-X of the GETGOAL program assessing the efficacy and safety of lixisenatide (partnership with Zealand Pharma), a once-daily GLP-1 receptor agonist, in patients with type II diabetes, versus exenatide twice daily.
The Company’s prescription medicines include Lantus, which is an insulin band. The range of products in the field of diabetes also includes Apidra and Amaryl. The Company’s other prescription drugs are Lovenox, Taxotere, Plavix, Aprovel, Eloxatin and Multaq. On June 17, 2010, Jevtana, a new anti-cancer agent, was approved by the Food & Drug Administration (FDA). The eight international brands under consumer healthcare include Doliprane, Essentiale, No-Spa, Maalox, Enterogermina, Magne B6, Dorflex and Lactacyd.
Sanofi Pasteur, the vaccines division of Sanofi, has a range of human vaccines. Among the major vaccines there are the Polio/Pertussis/Hib vaccines, such as Pentacel and Pentaxim, along with influenza vaccines (Vaxigrip et Fluzone) against seasonal flu, meningitis and pneumonia vaccines (incuding. Menactra), adult booster vaccines (including Adacel) and travel and other endemics vaccines.
Merial is a wholly owned Sanofi subsidiary. Merial is a producer of animal health products with Frontline and Heartgard.
54 rue la Boetie
Company Web Links
- FDA probes cognitive impact of new cholesterol drugs
- UPDATE 3-U.S. FDA probes cognitive impact of new cholesterol drugs
- UPDATE 1-U.S. FDA asks Sanofi, Regeneron to assess cholesterol drug's cognitive risks
- U.S. FDA probes cognitive impact of new cholesterol drugs; Regeneron, Sanofi shares fall
- SEC scores partial win in insider trading case over 2009 Sanofi deal